|
|
Clinical effect of Ambroxol combined with Budesonide atomized inhalation in the treatment of neonatal pneumonia |
ZOU Zhao-cheng |
Department of Neonatology,Citic Huizhou Hospital,Guangdong Province,Huizhou 516006,China |
|
|
Abstract Objective To investigate the clinical effect of Ambroxol combined with Budesonide atomized inhalation in the treatment of neonatal pneumonia.Methods Altogether 80 cases of neonatal children with pneumonia who were admitted to our hospital from December 2016 to November 2017 were selected as study subjects.According to the random number table method,the children were divided into the control group(40 cases)and the observation group(40 cases).All children were given routine treatment measures.The control group was given atomized inhalation of Ambroxol on the basis of the routine treatment,and the observation group was given Ambroxol combined with Budesonide atomized inhalation.The tidal breathing indexes(respiratory rate,tidal volume,peak time ratio,peak expiratory flow rate)before and after treatment were compared between the two groups,and the clinical symptom relief time (the disappearance time of the voice,lip purpura,cough and breath shortness),hospitalization time,treatment effect and adverse reactions were compared between the two groups.Results There were no significant differences in the tidal breathing indexes between the two groups before treatment(P>0.05).The respiratory rate and peak expiratory flow rate of the two groups after treatment were lower than those before treatment,the tidal volume was more than that before treatment,peak time ratio and peak expiratory flow rate were higher than those before treatment,and the differences were statistically significant(P<0.05).The respiratory rate and peak expiratory flow rate in the observation group after treatment were lower than those in the control group,the tidal volume was more than that in the control group,peak time ratio and peak expiratory flow rate were higher than those in the control group,and the differences were statistically significant(P<0.05).The clinical symptom relief time and hospitalization time in the observation group were shorter than those in the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was 97.50%,which was significantly higher than that in the control group (80.00%),and the difference was statistically significant(P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion The combination of Ambroxol and Budesonide atomized inhalation can effectively improve the tidal breathing indexes of children,shorten the disappearance time of clinical symptoms,improve the therapeutic effect,and has a high clinical value,which is worthy of promotion.
|
|
|
|
|
[1] |
韩桂珍,金梅英,罗忠媛,等.盐酸氨溴索雾化吸入联合超短波治疗新生儿肺炎的效果研究[J].中国处方药,2015,13(5):4405-4406.
|
[2] |
施耀标,郭瑞娟.盐酸氨溴索联合布地奈德雾化吸入治疗新生儿肺炎临床价值分析[J].实用中西医结合临床,2016,16(4):33-34.
|
[3] |
陆敏,谈健飞.氨溴索联合布地奈德雾化吸入治疗新生儿肺炎的临床效果[J].中国生化药物杂志,2017,37(3):237-239.
|
[4] |
马希萍,应露蓉,范海玲.氨溴索联合布地奈德雾化吸入在新生儿肺炎治疗与干预中的效果观察[J].中国生化药物杂志,2017,37(8):122-123.
|
[5] |
骆书辉.布地奈德联合氨溴索雾化吸入治疗新生儿肺炎的有效性及安全性[J].临床医学研究与实践,2016,1(11):112.
|
|
()()
|
[6] |
刘晓红,翟淑芬,张瑞敏.氨溴索联合布地奈德治疗新生儿肺炎临床效果评价及安全性分析[J].河北医药,2017,39(12):1824-1826.
|
[7] |
邱晓莉.吸入氨溴索联合布地奈德雾化溶液在新生儿肺炎治疗中的临床应用[J].陕西医学杂志,2017,46(4):529-530.
|
[8] |
张映红,马兰.探讨氨溴索静脉滴注加雾化吸入治疗新生儿肺炎效果[J].医药前沿,2015,5(28):198-199.
|
[9] |
池卫明,廖华.系统评价盐酸氨溴索注射液静脉滴注联合雾化吸入治疗新生儿肺炎的疗效和安全性[J].中国药房,2016,27(3):341-344.
|
[10] |
应燕芬,王丽珍,卢洪萍,等.盐酸氨溴索雾化吸入及肺部理疗辅助治疗新生儿肺炎的疗效观察[J].浙江医学,2017,39(17):1476-1477.
|
[11] |
赵文华,王惠萍.盐酸氨溴索雾化吸入治疗新生儿肺炎的疗效分析[J].药物评价研究,2017,40(2):255-257.
|
[12] |
何涓.盐酸氨溴索静注联合鼻塞式持续正压通气对新生儿肺炎血气指标的影响[J].中国妇幼保健,2016,31(11):2324-2325.
|
[13] |
段捷华,覃睿.盐酸氨溴索注射液在国内儿科临床的应用进展[J].医学综述,2015,21(8):1438-1440.
|
[14] |
刘美珍,曾德润,胥晓慧,等.氨溴索对新生儿肺炎血清炎性介质、心肌酶谱及肺功能的影响[J].海南医学院学报,2016,22(14):1567-1568.
|
[15] |
芦红茹,成大欣,马小宁,等.氨溴索对新生儿肺炎TB淋巴细胞亚群及免疫球蛋白的影响观察[J].河北医学,2016,22(11):1771-1774.
|
[16] |
孔永红.氨溴索对新生儿肺炎肺换气、肺通气与支气管黏膜纤毛结构的影响研究[J].临床肺科杂志,2017,22(8):1451-1453.
|
|
|
|